Logo image
Immunosuppression on the horizon
Journal article   Peer reviewed

Immunosuppression on the horizon

Howard J Eisen
Heart failure clinics, v 3(1), pp 43-49
Jan 2007
PMID: 17545008

Abstract

Abatacept Alemtuzumab Animals Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Antibodies, Neoplasm - therapeutic use Antineoplastic Agents - therapeutic use Calcineurin Inhibitors Cyclosporine - therapeutic use Everolimus Graft Survival - drug effects Graft Survival - immunology Heart Failure - epidemiology Heart Failure - surgery Heart Transplantation - methods Heart Transplantation - mortality Humans Immunoconjugates - therapeutic use Immunosuppression Immunosuppressive Agents - immunology Immunosuppressive Agents - therapeutic use Janus Kinase 3 - antagonists & inhibitors Kidney Failure, Chronic - epidemiology Kidney Failure, Chronic - surgery Prognosis Protein Kinases - therapeutic use Sirolimus - analogs & derivatives Sirolimus - therapeutic use Tacrolimus - immunology TOR Serine-Threonine Kinases
Many novel immunosuppressive agents are under active clinical investigation. In addition, creative approaches are being developed for the use of established immunosuppressive agents, with the goal of minimizing immunosuppression as early as possible posttransplantation. The hope is that these approaches will minimize the toxicity of these agents without sacrificing efficacy. Evidence suggests that the nephrotoxicity of calcineurin inhibitors can be reduced using these approaches. The introduction of newer immunosuppressive agents, including the proliferation signal inhibitors, raises the possibility that some of the long-term scourges of cardiac transplantation, including cardiac allograft vasculopathy and malignancy, can be ameliorated. Finally, costimulatory pathway inhibitors and other new immunosuppressive agents offer hope that all these goals can be accomplished with very low long-term maintenance immunosuppression.

Metrics

8 Record Views
11 citations in Scopus

Details

Logo image